← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV26행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
TCR (E6 T Cell Receptor, E6 T Cell Receptor (TCR))
iCell Gene Therapeutics·Human Papillomavirus
61 trials
Overview
Program
E6 T Cell Receptor (TCR)
Overview
Company
iCell Gene Therapeutics
Overview
Modality
CGT
Overview
Target
Human Papillomavirus
Overview
Indication
Human Papillomavirus; HPV-16
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Vector
AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways
MoA
Mechanism
, using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples
MoA
Biomarker
PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high
PK/PD
Species
Mouse, However
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse, However
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway.. Mucosal-associated invariant T (MAIT) cells recognize metabolite-derived ligands, but the identity of such ligands in the context of cancer remains poorly defined. Herein, we demonstrate that the tumor-derived metabolite 5-formyl tetrahydrofolate (5-formyl THF), which is an intermediate of the …
Toxicology
CRS
Reported
Clinical
Safety signal
Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway.. Mucosal-associated invariant T (MAIT) cells recognize metabolite-derived ligands, but the identity of such ligands in the context of cancer remains poorly defined. Herein, we demonstrate that the tumor-derived metabolite 5-formyl tetrahydrofolate (5-formyl THF), which is an intermediate of the …
Clinical
Selected reported efficacy
50%
Clinical
Result source
ClinicalTrials.gov NCT05943990
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT05943990